|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{SI}}
| | #redirect:[[Management of the thrombotic lesion]] |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| The presence of angiographically apparent thrombosis associated with adverse outcomes during the performance of PCI.
| |
| | |
| ==Treatment==
| |
| ===Glycoprotein 2b3a inhibition===
| |
| Glycoprotein 2b3a inhibition is effective in those patients who are troponin positive, and there is a consensus that they are useful in those patients with angiographically visible clot.
| |
| | |
| ===Thrombus Aspiration===
| |
| In the setting of ST segment elevation MI, mechanical aspiration of thrombus has been associated with improved myocardial perfusion and improve survival.
| |
| | |
| ===Direct Stenting===
| |
| It has been speculated that the direct stenting minimizes distal embolization. This approach has been associated with reduced risk of myonecrosis in meta-analyses.
| |
| | |
| ===Intracoronary Fibrinolytic Therapy===
| |
| For those clots that are resistant to thrombus aspiration, intracoronary fibrinolytic therapy is a consideration. Doses of up to 20 mg of tPA administered at a dose of 2 mg at a time are conventionally used.
| |
| | |
| ===Distal Protection===
| |
| Distal protection has been associated with a reduced risk of myonecrosis, particularly in saphenous vein graft lesions. It's utility native coronary arteries is not well demonstrated.
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiology]]
| |
| [[Category: Up-To-Date]] | |
| [[Category: Up-To-Date Cardiology]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |